RxDoctor Payments Data

Lucyana Panjaitan

Nurse Practitioner · Riverside, CANPI 1831656578

Payments from drug & device makers

$9,813in general payments, 2019–2025

Across 430 payments — averaging $22.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$857
  • Johnson & Johnson$837
  • Seagen Inc.$645
  • Amgen$615
  • Incyte Corporation$511
  • Sanofi$461
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$8,21084%
  • Education$1,60316%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis46$857
Johnson & Johnson(2 entities)23$837
Seagen Inc.17$645
Amgen28$615
Incyte Corporation17$511
Sanofi26$461
Astellas Pharma US Inc17$386
Bristol Myers Squibb19$343
E.r. Squibb & Sons, L.L.C.15$276
AstraZeneca(2 entities)13$262
Sanofi-aventis U.S. LLC3$252
Pharmacyclics LLC, An Abbvie Company10$249
GSK14$245
Merck10$238
Regeneron Healthcare Solutions, Inc.6$231
Takeda Pharmaceuticals U.S.A., Inc.6$224
Pfizer12$210
Karyopharm Therapeutics Inc.8$193
AVEO Pharmaceuticals, Inc.7$177
Lilly USA, LLC12$161
Puma Biotechnology, Inc.6$150
Gilead8$139
Eisai Inc.7$132
Bayer7$129
Daiichi Sankyo Inc.5$116
AbbVie6$113
Array Biopharma Inc5$111
Dova Pharmaceuticals4$90
Morphosys, US Inc.4$88
CSL Behring4$88
Taiho Oncology, Inc.5$85
Rigel Pharmaceuticals, Inc.3$81
Sobi, Inc3$79
Genentech USA, Inc.4$77
Boehringer Ingelheim4$73
Tersera Therapeutics LLC3$66
Blueprint Medicines Corporation3$64
Myovant Sciences Inc.4$55
Beigene USA, Inc.2$53
Octapharma USA, Inc.3$53
Deciphera Pharmaceuticals Inc.3$52
EUSA Pharma (US) LLC3$48
ADC Therapeutics America, Inc.2$45
Acrotech Biopharma Inc.2$38
Alnylam Pharmaceuticals Inc.2$38
Sun Pharmaceutical Industries Inc.1$37
Sumitomo Pharma America, Inc.2$35
AMAG Pharmaceuticals, Inc.1$34
Pharmaessentia USA Corporation1$33
Emmaus Medical, Inc.2$32
Jazz Pharmaceuticals Inc.1$28
Global Blood Therapeutics, Inc.2$28
GE HealthCare1$24
Adaptive Biotechnologies Corporation1$23
Mylan Institutional Inc.1$23
Mirati Therapeutics, Inc.1$16
Kyowa Kirin, Inc.1$14
Novocure Inc.1$14
Tactile Systems Technology Inc1$13
Chiesi USA, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,813 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sofosbuvir-VelpatasvirSofosbuvir/Velpatasvir20$130,977
OzempicSemaglutide28$20,757
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm36$9,490
JardianceEmpagliflozin21$8,084
Humulin N KwikpenInsulin Nph Human Isophane30$6,462
Humulin NInsulin Nph Human Isophane22$5,580
Humulin RInsulin Regular, Human24$4,257
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm11$3,269
Lactulose22$1,194
Glipizide91$1,186
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl38$845
Metformin Hcl51$621
Entecavir11$428
Atorvastatin Calcium21$258
Metformin Hcl ErMetformin Hcl19$190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCHumulin N, Humulin 70-30$161$8,84933 claims
Boehringer IngelheimJardiance$73$8,08421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →